Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

20 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

canagliflozin Articles

FDA panel backs J&J diabetes drug Invokana (canagliflozin)

11 January 2013

Regulatory briefs on vortioxetine, canagliflozin/metformin combo and Rescula

13 December 2012

Type 2 diabetes drug sales to almost double to nearly $50 billion in 2021

16 October 2012

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27 June 2012

Janssen files NDA with FDA for canagliflozin in type 2 diabetes

1 June 2012

Russia’s type 2 diabetes drug market will grow to $1.7 billion in 2015

13 October 2011

Highlights of ADA meeting see good results for canagliflozin, Victoza, dapagliflozin, Lantus & Apidra and taspoglutide

28 June 2010

Showing 1-7 of 7 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Encouraging results with Sangamo's SB-728-T in HIV treatment
  • Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
  • New study shows UCB's Neupro reduces NSBP in RLS patient

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS